| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Methyl methyl styraxate IVa (3-30 μM; 7-25 h) inhibited the production and gene expression of pro-inflammatory mediators in LPS-induced RAW264.7 macrophages in a concentration-dependent manner, through the inhibition of the expression of iNOS, COX-2, TNF-α, IL-6 and IL-1β [1]. Methyl methyl styraxate IVa (3-30 μM; 1 h pretreatment followed by 15-45 min/18 h LPS treatment) inhibited the activation of NF-κB and AP-1 in LPS-induced RAW264.7 macrophages in a concentration-dependent manner, through the inhibition of nuclear translocation of NF-κB p65 and expression/phosphorylation of c-Fos [1]. Methyl styraxate IVa (12.5-100 μM; 24 h) inhibited the proliferation of HCT116 cells, with cell viability decreasing at 25 μM and severe cell death at levels above 50 μM [2]. Methyl succinate of chikusetsusaponin IVa (10-40 μM) induced G0/G1 phase cell cycle arrest in HCT116 cells [2]. Methyl succinate of chikusetsusaponin IVa (20-30 μM; 4-24 h) downregulated the expression of cyclin D1, CDK2 and CDK4 in HCT116 cells in a time- and dose-dependent manner, and upregulated the expression of p21 [2]. Methyl succinate of chikusetsusaponin IVa (20-30 μM; 24 h) reduced the binding of β-catenin to TBE in HCT116 cells in a dose-dependent manner [2]. Methyl succinate of chikusetsusaponin IVa (20-30 μM; 24 h) reduced the nuclear β-catenin level in HCT116 cells in a dose-dependent manner [2].
|
|---|---|
| Cell Assay |
RT-PCR[1]
Cell Types: RAW264.7 Tested Concentrations: 3 μM, 15 μM, 30 μM Incubation Duration: Pretreatment for 1 hour, followed by stimulation with LPS for 6 hours Experimental Results: Concentration-dependent inhibition of mRNA expression of iNOS, COX-2, TNF-α, IL-6 and IL-1β. Western Blot Analysis [1] Cell Types: RAW264.7 Tested Concentrations: 3 μM, 15 μM, 30 μM Incubation Duration: Pretreatment for 1 hour, followed by stimulation with LPS for 24 hours Experimental Results: Concentration-dependent inhibition of protein expression of iNOS, COX-2, TNF-α, IL-6 and IL-1β. Cell viability assay [2] Cell Types: HCT116 colon cancer cells Tested Concentrations: 12.5, 25, 50 and 100 μM Incubation Duration: 24 hours Experimental Results: Cell proliferation was reduced at 25 μM and 50 μM; concentrations above 50 μM led to severe cell death.
|
| References |
|
| Molecular Formula |
C43H68O14
|
|---|---|
| Molecular Weight |
808.99
|
| CAS # |
58546-61-5
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1OC([C@]23[C@](CC(C)(CC3)C)([H])C4=CC[C@@]([C@@]5([C@@](C(C)([C@H](CC5)O[C@@H]6O[C@@H]([C@H]([C@@H]([C@H]6O)O)O)C(OC)=O)C)([H])CC7)C)([H])[C@]7(C)[C@@]4(CC2)C)=O
|
| Synonyms |
CME
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2361 mL | 6.1805 mL | 12.3611 mL | |
| 5 mM | 0.2472 mL | 1.2361 mL | 2.4722 mL | |
| 10 mM | 0.1236 mL | 0.6181 mL | 1.2361 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
